Jennifer Witt, MD
Neurology · Kirkland, WANPI 1538352836
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Medtronic at 27.5% of the total. Reporting peaked in 2024 at $1,978 and has fallen 51.0% since, to $969 in 2025.
Across 97 payments — averaging $55.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Boston Scientific$1K
- Stryker$508
- Vertex$450
- AbbVie$290
- Merz Pharmaceuticals, LLC$222
- plus $1K from 21 others
Across 25 payments — averaging $4115.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$61K
- Biohaven Pharmaceuticals, Inc.$39K
- Biohaven Pharmaceutical Holding Company Ltd.$3K
What the payments were for
- Consulting fees$4508%
- Speaking & faculty fees$471%
- Travel & lodging$2,20741%
- Food & beverage$2,65350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $1,472 |
| Boston Scientific | 14 | $1,218 |
| Stryker | 1 | $508 |
| Vertex | 1 | $450 |
| AbbVie(2 entities) | 11 | $290 |
| Merz Pharmaceuticals, LLC | 8 | $222 |
| Abbott | 2 | $184 |
| TG Therapeutics, Inc. | 7 | $140 |
| Acadia Pharmaceuticals Inc | 5 | $105 |
| Teva Pharmaceuticals USA, Inc. | 4 | $92 |
| Acorda Therapeutics, Inc | 3 | $70 |
| MDD US Operations, LLC | 2 | $64 |
| Novartis | 3 | $64 |
| Neurocrine Biosciences, Inc. | 3 | $64 |
| CSL Behring | 3 | $62 |
| Supernus Pharmaceuticals, Inc. | 2 | $55 |
| Bristol Myers Squibb | 3 | $53 |
| SK Life Science, Inc. | 2 | $47 |
| Amneal Pharmaceuticals LLC | 2 | $39 |
| Eisai Inc. | 1 | $27 |
| Sanofi | 1 | $23 |
| Insightec,inc | 1 | $22 |
| Adamas Pharmaceuticals, Inc. | 1 | $21 |
| UCB, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $16 |
| Banner Life Sciences, LLC | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCEPT PC BRAINSENSE$1,075
- SPECTRA WAVEWRITER$981
- 1688$508
- INFINITY$141
How this compares
$5,358 in reported general payments places this provider in the 80th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 157 | $320,406 |
| NuplazidPimavanserin Tartrate | 51 | $273,196 |
| GocovriAmantadine Hcl | 52 | $131,919 |
| NourianzIstradefylline | 19 | $76,647 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 403 | $35,658 |
| NeuproRotigotine | 24 | $21,149 |
| OngentysOpicapone | 22 | $18,077 |
| MyrbetriqMirabegron | 23 | $17,755 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 411 | $16,623 |
| Rasagiline Mesylate | 96 | $15,256 |
| Entacapone | 77 | $12,505 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 19 | $9,430 |
| Droxidopa | 21 | $8,807 |
| Ropinirole ErRopinirole Hcl | 31 | $6,795 |
| Selegiline Hcl | 46 | $5,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $39 | $320,406157 claims |
| Acadia Pharmaceuticals IncNuplazid | $105 | $273,19651 claims |
| MDD US Operations, LLCGocovri | $64 | $131,91952 claims |
| UCB, Inc.Neupro | $19 | $21,14924 claims |
| Neurocrine Biosciences, Inc.Ongentys | $64 | $18,07722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 418 neurology providers in Washington.
Other neurology in Kirkland
- Pinky AgarwalKirkland$795K
- James BowenKirkland$379K
- Jason PoonKirkland$102K
- Arash FazlKirkland$71K
- James SongKirkland$31K
- Casey NazorKirkland$10K
- Daniel BurdickKirkland$6K
- Pavle RepovicSeattle$1.1M
- Jason AldredSpokane$1M
- Stacy DonlonTacoma$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.